More effective and safer vaccines for animal and human health

Vireo Vaccines International develops novel, patent-protected vaccines and diagnostics to fight infectious diseases in cattle, poultry and people.

Two scientists in masks and lab coats working at a laboratory bench

What we do

Vaccines and diagnostics for tuberculosis, Johne’s disease, avian influenza and avian coronavirus.

Vireo Vaccines International (VVI) develops novel, patent-protected vaccines to improve human and animal health by preventing key diseases such as tuberculosis, Mycobacterium avium complex, and avian influenza. VVI also delivers advanced vaccines and diagnostics aimed at controlling Johne’s disease in cattle, as well as Avian Influenza and Avian Coronavirus (Infectious Bronchitis Virus) in poultry.

Guided by a vision to provide safer and more effective vaccines that enhance both human and livestock health, VVI focuses on designing next-generation solutions that strengthen biosecurity and disease prevention. In addition to its own innovations, the company supports strategic partners by assisting in the testing and development of their products.

VVI’s products and services benefit researchers, farmers, technicians, veterinarians, and veterinary laboratories worldwide — treating every customer as a partner, because their success is our success.

Our promise

Every product we develop meets our highest standards.

  • Safe
  • Simple
  • Effective
  • Proven

At Vireovac, we are dedicated to delivering vaccines that are safe, simple, effective, and proven. Each product is developed to the highest standards of quality and safety, designed with both animals and farmers in mind. Our vaccines ensure ease of use and maximum protection, helping reduce infections without compromising host immunity.

Backed by rigorous laboratory and field testing, our vaccines have demonstrated their ability to lower infection rates, prevent disease spread, and minimize side effects. Trusted by scientists, industry experts, and farmers alike, Vireovac products represent a reliable and innovative approach to animal health.

Research

Peer-reviewed work behind our vaccine programs.

Patents

Three issued and five pending.

  • Immunogenic Compositions Against Tuberculosis

    Inventors: Adel M. Talaat, Bassam Abomoelak and Sarah K. Ward

    US 8,367,055 B2 Issued
  • Vaccine Candidates Against Johne’s Disease

    Inventor: Adel M. Talaat

    US 8,758,773 Issued
  • Global gene regulators (GGR) as vaccine candidates against paratuberculosis

    Inventor: Adel M. Talaat

    US 10,544,389 Issued
  • RNA Biomarkers for Early Diagnosis of Mycobacterial Infections

    Inventor: Adel M. Talaat

    WARF: P130075US01 Pending
  • A universal vaccine against Infectious Bronchitis Virus, Avian Influenza, Newcastle Disease Virus and Infectious Bursal Disease

    Inventors: Adel M. Talaat and Brock Bakke

    WARF: P190239US01 Pending
  • WARFplex: A novel adjuvant for animal and human vaccines

    Inventors: Adel M. Talaat and Sekar Chandrasekar

    WARF: P190189US02 Pending
  • Neutralizing Vaccines Against Human Coronavirus

    Inventors: Adel M. Talaat and Sekar Chandrasekar

    WARF: P210042US01 Pending
  • Modified Gene Vaccines Against Avian Coronavirus

    Inventors: Adel M. Talaat and Sekar Chandrasekar

    WARF: P210169 Pending

Latest news

Stay updated with our latest developments.

Dairy cattle standing in a barn

A Single-Dose Polyanhydride-Based Nanovaccine Against Paratuberculosis

Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) causes Johne’s disease in ruminants and is characterized by chronic gastroenteritis leading to heavy economic losses to the dairy industry worldwide. The currently available vaccine (inactivated bacterin in oil base) is not effective in preventing pathogen shedding and is rarely used to control Johne’s disease in dairy herds.

Read the paper
Illustration of virus particles

Effective Mosaic-Based Nanovaccines Against Avian Influenza in Poultry

Avian influenza virus (AIV) is an extraordinarily diverse pathogen that causes significant morbidity in domesticated poultry populations and threatens human life with looming pandemic potential. Controlling avian influenza in susceptible populations requires highly effective, economical and broadly reactive vaccines.

Read the paper
Fluorescence microscopy image of green-labelled cells

Protective RNA

The induction of an effective immune response is critical for the success of mRNA-based therapeutics. Here, we developed a nanoadjuvant system compromised of Quil-A and DOTAP (dioleoyl 3 trimethylammonium propane), hence named QTAP, for the efficient delivery of mRNA vaccine constructs into cells.

Read the paper
Circular genome map of M. avium subsp. paratuberculosis JQ5 from Camelus dromedarius

Johne’s Disease in Middle East Camels

Mycobacterium avium subspecies paratuberculosis (M. ap) is the causative agent of paratuberculosis or Johne's disease (JD) in herbivores with potential involvement in cases of Crohn's disease in humans. JD is spread worldwide and is economically important for both beef and dairy industries.

Read the paper

Work with Vireo Vaccines

For partnerships, licensing and testing services, get in touch by email. We treat every customer as a partner, because their success is our success.

Email
adel.talaat@vireovaccines.com
Location
Madison, Wisconsin, USA
Email us